default author photo

Mingfu Wu

Huazhong University of Science and Technology

SCHOLARLY PAPERS

1

DOWNLOADS

34

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Neoadjuvant Niraparib Monotherapy for Newly Diagnosed Unresectable HRD-Positive High-Grade Serous Ovarian Cancer (NANT): A Multicenter, Prospective, Phase 2 Trial

Number of pages: 31 Posted: 09 Feb 2026
Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Sichuan University, Sun Yat-sen University (SYSU), Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology - Department of Radiology, Huazhong University of Science and Technology, Huazhong University of Science and Technology (Formerly Tongi Medical University) - National Clinical Research Center for Gynecology and Obstetrics, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Shandong University, Wuhan University, Sichuan University, Sichuan University, Sichuan University, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, University of California, San Francisco (UCSF), Zai Lab (Shanghai) Co, Ltd., Precision Scientific (Beijing) Co., Ltd., Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Huazhong University of Science and Technology, Guangdong Academy of Medical Sciences, Huazhong University of Science and Technology - Hubei Cancer Hospital, Independent, Shandong University, Wuhan University - Department of Gynecology and Obstetrics, Huazhong University of Science and Technology - Department of Obstetrics and Gynecology, Huazhong University of Science and Technology and Huazhong University of Science and Technology - Cancer Biology Research Center
Downloads 34 (1,263,436)

Abstract:

Loading...

Ovarian cancer, neoadjuvant therapy, PARP inhibitor, homologous recombination deficiency